Trial
NCT02739360
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Lymphoid Malignancies
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-04